Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…Abstract Number: 2629 • ACR Convergence 2025
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
Background/Purpose: Social Determinants of Health (SDOH) are increasingly recognized as significant contributors to adverse outcomes in pregnant patients with SLE. This study aims to evaluate…Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…Abstract Number: 1077 • ACR Convergence 2025
Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
Background/Purpose: Work status and employment can be impacted in people with inflammatory arthritis (IA). We aimed to assess the association between health literacy and work…Abstract Number: 0381 • ACR Convergence 2025
Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
Background/Purpose: The purpose of Research Accelerated by You (RAY) is to amplify awareness about clinical research and trials and ensure lupus patient partnership in therapeutic…Abstract Number: 2615 • ACR Convergence 2025
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…Abstract Number: 1704 • ACR Convergence 2025
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
Background/Purpose: Social determinants of health (SDOH) operate across individual, family, and community levels. We previously demonstrated that cumulative social disadvantage, comprised of individual and family-level…Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…Abstract Number: 0368 • ACR Convergence 2025
Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
Background/Purpose: Home-based telemedicine is an efficient healthcare delivery approach. A recent randomized clinical trial (RCT) found that in-person visits may be preferred among rheumatology patients.…Abstract Number: 2565 • ACR Convergence 2025
Assessing Participation in the Lupus Sister Circle Support Group
Background/Purpose: Relative to White people with lupus (PWL), Black/African American (B/AA) PWL are three times as likely to develop lupus and suffer a severe form…Abstract Number: 1689 • ACR Convergence 2025
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…Abstract Number: 0364 • ACR Convergence 2025
Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey
Background/Purpose: Clinical trials are the cornerstone of evidence-based rheumatology, yet enrolling and retaining a representative patient cohort remains challenging. While underrepresentation of underserved minorities is…Abstract Number: 2518 • ACR Convergence 2025
Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis associated with significant morbidity and complex care needs across a broad demographic…Abstract Number: 1633 • ACR Convergence 2025
Social Determinants of Health and Adverse Perinatal Outcomes in Women with Rheumatic Diseases
Background/Purpose: Social determinants of health (SDH) are the conditions in which individuals are born, grow, live and work. These factors (education, socioeconomic status, access to…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 22
- Next Page »